Amgen Statement on Pricing
Amgen takes seriously our commitment to ensuring access and affordability for our patients. To that end, on Amgen’s Q2 earnings call we announced a decision not to increase the prices of our medicines at mid-year, and that we have no plans to change that decision for the balance of the year. Specifically, this decision was made given the current climate on drug pricing, including the new environment post-Trump Administration’s request for information release in May. This reflects our commitment to identifying opportunities to improve affordability and access for patients, and we look forward to working with the Administration and Congress on these important issues. While there are no simple fixes, we want to be part of the solution.